Shots: COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study In Dec’2015, Takeda and COUR collaborated to develop therapies for celiac disease, provided Takeda an exclusive option to acquire a WW license […]Read More
Shots: Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months The P-III clinical study is the one of key event for addressing needs of Celiac patients with continued symptoms despite being on a gluten-free diet Innovate focuses on developing […]Read More
Shots: Amgen to make $20M investment in Provention and also has option to license AMG-714 (after completion of P-IIb), if exercised will pay $150M as upfront plus milestones and royalties to Provention Provention to fund and conduct the P-IIb trial for PRO-015 (AMG 714) and holds commercialization rights (if not exercised by Amgen) while giving […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
